The Miracle Arrives With a $3.2 Million Invoice
Here is the money trail presented by the scenario: children’s-hospital and academic micro-dystrophin research tied to Nationwide Children’s Hospital moves into Sarepta’s private commercialization pipeline, and the number waiting at the end is $3.2 million. Nationwide is presented as receiving licensing and royalty revenue; families and payers are presented as facing the cost. That is a remarkable invoice-routing system: the science gets described as a shared triumph, while the people who need it are treated like they wandered into the pricing meeting without a badge.
Profit is not the villain. Pretending the public-private pipeline ends at “innovation” is. If the figure and licensing arrangement are accurate as presented, the contradiction is hard to miss: the breakthrough gets inspirational music, the commercial deal gets revenue, and the family gets a financial document written in the ancient language of “please indicate which organ you’d like to sell first.” Nobody has to oppose useful medicine or licensing to ask why the people carrying the medical and financial risk get no meaningful seat at the pricing table.